Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its aPKCi inhibitor platform, a potential breakthrough in treating hedgehog pathway-dependent cancers. …
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the appointment of Leanne Kelly to its board of directors. Kelly, a seasoned financial executive with extensive public company experience, will …
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy Read More WARRINGTON, PA — Windtree Therapeutics, Inc. announced a bold new plan to establish itself as a revenue-generating biotechnology company by acquiring small businesses with FDA-approved products. At the same time, the …
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular Clinical Trials Conference in Washington, DC. The …
Windtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic Shock Read More WARRINGTON, PA — Windtree Therapeutics, Inc. has announced a new patent application for istaroxime derivatives, aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing builds on encouraging …
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has partnered with New Growth Advisors (NGA), a prominent life sciences consulting firm, to explore strategic options for its cardiovascular portfolio. The …
Windtree Therapeutics Engages New Growth Advisors to Explore Strategic Opportunities Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced its financial results for the third quarter ending September 30, 2024, alongside significant business updates. The company achieved progress in …
Windtree Therapeutics Reports Q3 Results and Highlights Key Business Achievements Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant leadership change as Craig Fraser steps down from his role as Chief Executive Officer, effective December 1, 2024. …
Leadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes Helm Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent for istaroxime in Hong Kong, titled “Istaroxime-containing intravenous formulation for the treatment of heart …
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C cardiogenic shock. This trial marks a pivotal step in …
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock Read More